NCT07699562 ICU CONNECT: Study Comparing EMG in Healthy Volunteers and ICU Patients.
| NCT ID | NCT07699562 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Endeavor Health |
| Condition | ICU Acquired Weakness |
| Study Type | INTERVENTIONAL |
| Enrollment | 24 participants |
| Start Date | 2026-06 |
| Primary Completion | 2027-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 24 participants in total. It began in 2026-06 with a primary completion date of 2027-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is testing whether a non-invasive nerve monitoring device (TetraGraph) can accurately detect early signs of ICU-acquired weakness by comparing readings from the device with standard nerve conduction/EMG tests done by a specialist to see if they match. They will focus on muscle response signals in the hand and leg over about 10 days in three groups: healthy volunteers, ICU patients who are not on ventilators, and ICU patients who are on ventilators.
Eligibility Criteria
Inclusion Criteria: * Cohort 1: Healthy volunteers Inclusion criteria: * Subjects must be \> 18 years old and \< 90 years old. * Subjects must consent to participate. Cohort 2: Non-intubated critically ill patients Inclusion criteria: * Subjects may be male or female. * Subjects must be \> 18 years old and \< 90 years old. * Subjects must have a POA or next of kin who is able to consent (for those in the ICU and who are unable to consent themselves). Cohort 3: Intubated critically ill patients Inclusion criteria: * Subjects may be male or female. * Subjects must be \> 18 years old and \< 90 years old. * Subjects must have a POA or next of kin who is able to consent (for those in the ICU and who are unable to consent themselves). * For the Subjects in the ICU that are intubated, they must be planned to be intubated for at least 24 hours. * Subjects must be intubated for no longer than ≥ 72 hours before enrollment. Exclusion Criteria: * Cohort 1: Healthy volunteers Exclusion criteria: * Subjects with previous paralysis or neuromuscular disease. * Subjects with spinal cord or brain injuries that impact motor function. * Subjects with an allergy to clinical adhesive or hydrogel. Cohort 2: Non-intubated critically ill patients Exclusion criteria: * Subjects with previous paralysis or neuromuscular diseases. * Subjects with previous peripheral nerve injuries to the tested limbs. * Subjects with spinal cord or brain injuries (including stroke) that impact motor function. * Subjects without a POA or next of kin for those patients that are unable to consent themselves. * Subjects with an allergy to clinical adhesive or hydrogel. Cohort 3: Intubated critically ill patients Exclusion criteria: * Subjects with previous paralysis or neuromuscular disease * Subjects with previous peripheral nerve injuries to the tested limbs. * Subjects with spinal cord or brain injuries that impact motor function. * Subjects without a POA or next of kin for those patients that are in the intubated arm. * Subjects with intubations expected to last less than 24 hours. * Subjects who have already been intubated for \> 72 hours. * Subjects with an allergy to clinical adhesive or hydrogel.
Contact & Investigator
Cliodhna Ashe, MD
PRINCIPAL INVESTIGATOR
Endeavor Health
Frequently Asked Questions
Who can join the NCT07699562 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying ICU Acquired Weakness. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07699562 currently recruiting?
Yes, NCT07699562 is actively recruiting participants. Contact the research team at jessica.brickner@endeavorhealth.org for enrollment information.
Where is the NCT07699562 trial being conducted?
This trial is being conducted at Evanston, United States.
Who is sponsoring the NCT07699562 clinical trial?
NCT07699562 is sponsored by Endeavor Health. The principal investigator is Cliodhna Ashe, MD at Endeavor Health. The trial plans to enroll 24 participants.